14.12.2006 – 20:15

Novasep

Solvay Pharmaceuticals and Novasep Have Signed a Strategic Manufacturing Alliance

Pompey, France (ots/PRNewswire)

Solvay Pharmaceuticals and
Novasep have signed a five-year strategic manufacturing alliance
which includes the exclusive synthesis of two active pharmaceutical
ingredients for Solvay Pharmaceuticals.

Solvay and Novasep have recently set a strategic manufacturing
alliance defining Novasep as a preferred partner for the development,
the scale-up and the industrial supply of existing or new chemical
entities and/or active pharmaceutical ingredients. Under the terms of
this 5-years agreement, Novasep currently implement the large scale
production of Pinaverium bromide and Betahistine in its Mourenx
facility.

As part of this alliance in the short and mid-term, Novasep and
Solvay Pharmaceuticals will start discussion on the possibility to
extend this agreement. This outsourcing is in line with Solvay
Pharmaceuticals strategy of shifting selected manufacturing
activities to high quality, competitively-priced alternatives.

Novasep Synthesis offers exclusive synthesis services utilizing
specialised technologies such as, for instance, chiral technologies,
hazardous chemistry, highly potent API to produce elaborate molecules
for the pharmaceutical industry and combines its exclusive synthesis
know-how and capabilities with its purification technology using
preparative chromatography to offer a pure and cost-effective API to
its customers.

Solvay is an international chemical and pharmaceutical Group with
headquarters in Brussels. It employs some 30,000 people in 50
countries. In 2005 its consolidated sales amounted to EUR 8.6 billion
generated by its three activity sectors: Chemicals, Plastics and
Pharmaceuticals. SOLVAY (Euronext : SOLB.BE - Bloomberg: SOLB.BB -
Reuters: SOLBt.BR) is listed on the Euronext stock exchange in
Brussels. Details are available at www.solvay.com

Novasep Synthesis provides R&D and exclusive synthesis, from lab
to industrial scale, with special expertise in hazardous chemistry,
chiral technologies, Highly Potent APIs and Early Stage Services.
Novasep Synthesis includes two business units: exclusive synthesis
andproprietary products.

Groupe Novasep covers the special needs of the pharmaceutical,
food, cosmetics, agrochemicals, and speciality chemicals industries.
It binds chemical synthesis and chemical engineering expertise in
order to develop new technologies. The group operates through two
divisions: Novasep Synthesis and Novasep Process focusing on the
synthesis and process of intermediates, advanced intermediates and
APIs.

For more information please visit Novasep's website
www.novasep.com

Press contact
    Jean-Marc Le Rudulier
    Marketing & Communication Director
    Groupe Novasep
    Bd de la Moselle
    B.P. 50
    54340 Pompey
    France
    Tel : +33(0)3-83-49-71-46
    Fax : +33(0)3-83-49-71-40
     jean-marc.le.rudulier@novasep.com
 www.novasep.com

Contact:

Press contact: Jean-Marc Le Rudulier, Marketing & Communication
Director, Groupe Novasep, Bd de la Moselle, B.P. 50, 54340 Pompey,
France, Tel : +33(0)3-83-49-71-46, Fax : +33(0)3-83-49-71-40,
jean-marc.le.rudulier@novasep.com, www.novasep.com